Keyphrases
Practice Effects
50%
Chemotherapy
50%
Breast Cancer
50%
Cognitive Impairment
50%
Dabrafenib
50%
Adjuvant Immunotherapy
50%
Prognostic Patterns
50%
Relapse Pattern
50%
Survival Outcomes
50%
Melanoma Survival
50%
Prognostic Factors
50%
Recurrence-free Survival
37%
Anti-PD-1
37%
Melanoma
37%
Adjuvant Therapy
25%
Resection
25%
Clinical Trials
25%
Executive Function
16%
Time to Discontinuation
16%
Number of Metastatic Sites
12%
Improved Outcomes
12%
Immune-related Adverse Events
12%
Brain Metastases
12%
Demographic Characteristics
12%
Real-world Outcomes
12%
Multicenter Observational Study
12%
Late Relapse
12%
Clinical Characteristics
12%
Primary Melanoma
12%
Early Relapse
12%
Melanoma Patients
12%
Attention Function
11%
Women with Breast Cancer
11%
Divided Attention
5%
Memory Fluency
5%
Executive Attention
5%
Post-chemotherapy
5%
Cyclophosphamide
5%
Taxanes
5%
Chemotherapy-related Cognitive Impairment
5%
Attention Memory
5%
5-fluorouracil (5-FU)
5%
Repeated Assessment
5%
Longitudinal Change
5%
Cognitive Performance
5%
Memory Function
5%
Memory-guided Attention
5%
Epirubicin
5%
Adverse Effects
5%
After Surgery
5%
Medicine and Dentistry
Melanoma
100%
Observational Study
58%
Trametinib
50%
Dabrafenib
50%
Immunotherapy
50%
Prognostic Factor
50%
Adjuvant Therapy
46%
Recurrence Free Survival
34%
Adverse Event
30%
Disease Exacerbation
20%
Survival Rate
18%
Clinical Trial
16%
Recurrent Disease
16%
Time to Treatment
10%
MEK Inhibitor
10%
Asthenia
10%
Overall Survival
10%
Fever
10%
Diarrhea
10%
Immune-Related Adverse Events
8%
Brain Metastasis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Observational Study
50%
Melanoma
50%
Trametinib
50%
Dabrafenib
50%
Adverse Event
30%
Disease Exacerbation
20%
Overall Survival
10%
Survival Rate
10%
Diarrhea
10%
Asthenia
10%
Recurrence Free Survival
10%
Mitogen Activated Protein Kinase Kinase Inhibitor
10%
Fever
10%
